These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 38211482)

  • 1. GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis.
    Banerjee M; Pal R; Maisnam I; Mukhopadhyay S
    Diabetes Metab Syndr; 2024 Jan; 18(1):102943. PubMed ID: 38211482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
    Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
    Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
    Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
    Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
    Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.
    Akbari A; Hadizadeh S; Heidary L
    J Diabetes Res; 2024; 2024():3212795. PubMed ID: 38529046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
    Edmonston D; Mulder H; Lydon E; Chiswell K; Lampron Z; Shay C; Marsolo K; Shah RC; Jones WS; Gordon H; Hwang W; Ayoub I; Ford D; Chamberlain A; Rao A; Fonseca V; Chang A; Ahmad F; Hung A; Hunt K; Butler J; Bosworth HB; Pagidipati N
    J Am Coll Cardiol; 2024 Aug; 84(8):696-708. PubMed ID: 39142723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Banerjee M; Pal R; Mukhopadhyay S; Nair K
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M; Maisnam I; Mukhopadhyay S
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):739-746. PubMed ID: 36696050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.
    Albulushi A; Tanoh DB; Almustafa A; Al Matrooshi N; Zolty R; Lowes B
    Cardiovasc Diabetol; 2024 Aug; 23(1):324. PubMed ID: 39217337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
    Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
    Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2617-2629. PubMed ID: 38466894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus.
    Zhang J; Van Spall HG; Li L; Khan MS; Pandey A; Thabane L; Bai X; Wang Y; Lip GY; Li G
    Diabetes Metab Syndr; 2023 Jul; 17(7):102804. PubMed ID: 37315473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
    Neves JS; Borges-Canha M; Vasques-Nóvoa F; Green JB; Leiter LA; Granger CB; Carvalho D; Leite-Moreira A; Hernandez AF; Del Prato S; McMurray JJV; Ferreira JP
    J Am Coll Cardiol; 2023 Aug; 82(6):517-525. PubMed ID: 37532422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.